June 3, 2024 02:49 PM EDT

At ASCO: big readouts, revenue questions, and the ups and downs of ADCs

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

CHICAGO – More than 40,000 clinicians, biopharma executives, investors, drug salespeople and many others involved in cancer research descended upon McCormick Place in Chicago for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

At ASCO: big readouts, revenue questions, and the ups and downs of ADCs

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

At AS­CO: big read­outs, rev­enue ques­tions, and the ups and downs of AD­Cs

Senior Reporter

News Reporter

Sign up to read this article for free.

more like this

At ASCO: big readouts, revenue questions, and the ups and downs of ADCs